PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

Core Insights - Pfizer Inc. and Astellas Pharma Inc. announced positive results from the Phase 3 EV-304 clinical trial for PADCEV (enfortumab vedotin) in combination with Keytruda (pembrolizumab) for patients with muscle-invasive bladder cancer eligible for cisplatin-based chemotherapy [1] Group 1 - The clinical trial is also known as KEYNOTE-B15 [1] - The combination therapy targets Nectin-4 and utilizes a PD-1 inhibitor [1] - The study focuses on perioperative treatment for muscle-invasive bladder cancer [1]